# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
In a recent letter to investors, Cathie Wood, the CEO of ARK Invest, highlighted the potential of the company's flagship fu...
Goldman Sachs analyst Matthew Sykes maintains Twist Bioscience (NASDAQ:TWST) with a Buy and raises the price target from $45...
Barclays analyst Luke Sergott maintains Twist Bioscience (NASDAQ:TWST) with a Overweight and raises the price target from $4...
TD Cowen analyst Steven Mah maintains Twist Bioscience (NASDAQ:TWST) with a Buy and raises the price target from $55 to $65.
Mid-cap stocks saw significant gains last week, with top performers like AGIO, VRNT, and NVAX, causing analysts to raise their ...
TB206-001 shown to be a high-affinity, cross-reactive humanized antibody antagonist of A2AR with in vivo tumor suppressing acti...